Link to Full Article Melbourne, Australia; 31 May 2021: As announced on 30 April 2021 Acrux Limited (ASX:ACR, “Acrux” or the “Company”) is pleased to confirm that the Company’s 100% owned investee company Acrux Pharma Pty Ltd has received approval from AusIndustry for an Advance and Overseas Finding application. The finding covers financial years 2018/19, […]
Link to Full Article Cambridge, United Kingdom – 27 May 2021 Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, has been featured in the UK’s Digital Health Playbook – ‘First 100’. An initiative the Department of International Trade to highlight the nation’s most innovative and impactful digital health companies. The First 100 list features UK businesses with a proven track record of benefiting […]
Link to Full Article Brighton, United Kingdom – 19 May 2021 – Destiny Pharma plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, as announced on 4 May 2021, will hold its 2021 Annual General Meeting (“AGM”) at the offices of finnCap Ltd, Destiny Pharma’s Nominated Advisor and […]
Link to Full Article Melbourne, Australia – 13 May 2021: Adherium Limited (ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions, announces the appointment of Rick Legleiter as Chief Executive Officer of Adherium. The Board also announces the appointment of George Baran as a Non-Executive Director. Mike Motion, Adherium’s current CEO and […]
Link to Full Article Company earns $750,000 milestone payment related to SWARM-P.a. Study MARINA DEL REY, Calif., May 13, 2021 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced results for the first quarter of 2021 and provided […]
Link to Full Article Results show ~90% overall back and leg responder rate, ~68% high responder rate, and zero explants due to loss of efficacy ~83% of patients reduced or eliminated opioid use Need for patient re-programming visits nearly eliminated after 12 months Represents the first peer reviewed SCS study to show responder and high […]
Link to Full Article Proceeds to be used to expand electrospinning capabilities & capacity, driving company growth Harwell, UK, May 4 2021 – The Electrospinning Company (Electrospinning), a leader in the development and manufacture of nanofibrous biomaterials for use in tissue regenerative devices, has completed a £4.5m ($6.3m) fundraising round, led US materials science company Confluent Medical Technologies Inc. (Confluent) […]
Link to Full Article Posting of Annual Report and Accounts, and Notice of AGM Brighton, United Kingdom – 4 May 2021 – Destiny Pharma plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, announces that the following documents are now available on the Company’s website at www.destinypharma.com […]
Link to Full Article MIP Diagnostics, a UK manufacturer of molecularly imprinted polymers (MIPs) has achieved ISO 9001:2015 accreditation. MIP Diagnostics specialise in the development and manufacture of nanoscale molecularly imprinted polymers (nanoMIPs), which act as synthetic antibodies in diagnostic assays, sensors and other industry applications. After a strong start to 2021, MIP Diagnostics has […]
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds: